What are the main side effects of Setmelanotide?

Setmelanotide side effects and warning signals include Skin hyperpigmentation, Injection site reactions, Nausea, Diarrhea, and Abdominal pain.

What evidence level is Setmelanotide?

Setmelanotide is rated Level A; the listed research status is FDA Approved.

Weight Loss & Metabolic / Level A / FDA Approved / Last reviewed 2026-04-04

Setmelanotide Evidence Guide

Setmelanotide (Imcivree) is FDA-approved for chronic weight management in patients with specific genetic obesity syndromes (POMC, PCSK1, or LEPR deficiency). In its approved population, it produces dramatic and clinically meaningful weight loss. Outside this narrow genetic indication, there is no evidence base. It is not a general obesity treatment - but for research into melanocortin pathway obesity, it is the only approved compound in its class.

Our Take

Best for: MC4R-pathway genetic obesity (POMC/PCSK1/LEPR deficiency), melanocortin pathway obesity research
Evidence grade: Level A
Confidence: High
Starting point: 2mg subcutaneous daily, titrated based on response and tolerability

Benefits and Evidence

Weight Loss in Genetic Obesity: Level A, includes human evidence - Patients with POMC deficiency achieved mean body weight reductions of approximately 25% over 1 year. LEPR-deficient patients achieved approximately 12% weight loss. Results are transformative for these rare conditions.
Hunger Reduction: Level A, includes human evidence - Dramatic reduction in insatiable hunger (hyperphagia) scores reported by patients and caregivers, greatly improving quality of life.
Skin Hyperpigmentation: Level A, includes human evidence - Skin darkening occurs in most patients due to residual MC1R activity. Generally cosmetic and reversible upon discontinuation.

Side Effects and Warnings

Skin hyperpigmentation
Injection site reactions
Nausea
Diarrhea
Abdominal pain
Spontaneous penile erection (due to melanocortin activity)
Depression
Only indicated for obesity due to confirmed POMC, PCSK1, or LEPR deficiency - not for general obesity

Research Dosage References

<strong>Subcutaneous injection</strong> - 2-3 mg (adults) - Once daily - FDA-approved dose. Start at 2 mg daily, may increase to 3 mg if weight loss is insufficient after 2 weeks. Inject in the abdomen.
<strong>Subcutaneous injection</strong> - 1-2 mg (pediatric, 6-11 years) - Once daily - Pediatric dosing starts at 1 mg, titrated based on response. Minimum age 6 years.

Mechanism of Action

Setmelanotide is a cyclic octapeptide that acts as an agonist at the melanocortin-4 receptor (MC4R), a key receptor in the hypothalamic leptin-melanocortin pathway that regulates energy balance, food intake, and energy expenditure. In normal physiology, leptin signaling in the arcuate nucleus of the hypothalamus activates POMC neurons, which produce alpha-melanocyte-stimulating hormone (alpha-MSH). Alpha-MSH then activates MC4R on paraventricular nucleus neurons, promoting satiety and increasing energy expenditure. Genetic deficiencies in POMC, PCSK1 (which processes POMC to alpha-MSH), or the leptin receptor disrupt this pathway, leading to severe, early-onset obesity with insatiable hunger. Setmelanotide bypasses these upstream genetic defects by directly activating MC4R, effectively substituting for the missing or reduced alpha-MSH signal. This restores satiety signaling and normalizes energy expenditure regulation in patients with these rare genetic conditions. Unlike previous MC4R agonists, setmelanotide was designed for improved receptor selectivity, with reduced activity at MC1R (which would cause skin darkening) and MC3R, though hyperpigmentation still occurs in some patients.

Legal Status

FDA approved (2020, Imcivree). Prescription required. Available through specialty pharmacy only. REMS program required.

Primary Sources

Setmelanotide for the treatment of POMC deficiency obesity: results of a Phase 3 trial. Nature Medicine, 2020.
MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nature Medicine, 2016.